CAML Assay for Early Detection

About Creatv Bio

Creatv Bio is a private diagnostics company pioneering a liquid biopsy platform focused on detecting large, phagocytic circulating cells called Cancer Associated Macrophage-Like Cells (CAMLs). Its core value proposition is the potential for early cancer detection and recurrence monitoring across more than 30 cancer types, using a standard blood draw. The company operates in both the clinical research and biopharma services markets, offering assays for patient stratification, therapy monitoring, and drug development support. Its technology differentiates by targeting CAMLs, which are present from early-stage disease, unlike traditional CTCs often found only in later stages.

Therapeutic Areas